Company Profile

Abzyme Therapeutics LLC
Profile last edited on: 10/7/22      CAGE: 62ES6      UEI: H2MLEFWV36N6

Business Identifier: Developing antibodies for diagnostic and therapeutic applications
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

321 Jones Boulevard Suite 300
Royersford, PA 19468
   (610) 990-7531
Location: Single
Congr. District: 04
County: Montgomery

Public Profile

Using proprietary protein evolution platforms and intracellular (iHuMab) and extracellular (eHuMab) genetic selection systems, Abzyme Therapeutics LLC is organized around generating and developing full-sized human monoclonal antibodies for treating a broad range of diseases. The firm has the capabilities of generating a highly diversified human antibody repertoire and establishing a tightly regulated selection system to isolate a single antigen-specific antibody-producing clone from billions. Abzyme Therapeutics is developing a pipeline of novel, targeted human monoclonal antibodies for the treatment of Alzheimer’s disease, cancer, autoimmune diseases, and infectious diseases. Led by an interdisciplinary team of successful industry professionals, Abzyme is introducing a pioneer technology to generate human monoclonal antibodies and exploit the enormous potential of antibody-based medicines.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Hiep T Tran -- President and Chief Scientific Officer

  Steve Manobianci -- Director of Business Development

  Andrew Phillips -- Research Scientist

  Rajesh Kumar Singh -- Lab Director

  Rolf Swoboda

  Alexander H Taylor -- Director Pre-Clinical studies

  Kirill Volkov -- Senior Scientist

Company News

There are no news available.